Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1962 Sep 1;116(3):311–327. doi: 10.1084/jem.116.3.311

EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS: THE EFFECT OF 6-MERCAPTOPURINE

Leon W Hoyer 1, Robert A Good 1, Richard M Condie 1
PMCID: PMC2137550  PMID: 14449435

Abstract

1. 6-Mercaptopurine (6-MP) prevents experimental allergic encephalomyelitis (EAE) during the period of drug administration in both rabbits and guinea pigs. The disease is suppressed even when treatment is started as late as the 5th day after antigenic stimulation in guinea pigs and the 12th day in rabbits. 2. After discontinuation of 6-MP treatment, there is a latent period before the disease is noted. The length of this latent period is not modified by the duration of 6-MP treatment. 3. The effect of 6-MP on EAE is not the result of leukopenia, non-specific toxicity and debilitation, anti-inflammatory activity, or mere masking of clinical signs of the disease. It is, rather, the result of 6-MP's specific anti-immunologic activity. 4. The effects of 6-MP on antibody production, delayed hypersensitivity, and EAE are compared. This provides indirect evidence for the importance of circulating antibody in the pathogenesis of EAE. 5. The important considerations in the use of 6-MP are discussed and the possible usefulness of 6-MP in human neurologic diseases is considered.

Full Text

The Full Text of this article is available as a PDF (856.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ADAMS R. D., KUBIK C. S. The morbid anatomy of the demyelinative disease. Am J Med. 1952 May;12(5):510–546. doi: 10.1016/0002-9343(52)90234-9. [DOI] [PubMed] [Google Scholar]
  2. ATKINSON M. R., JACKSON J. F., MORTON R. K. Substrate specificity and inhibition of nicotinamide mononucleotideadenylyl transferase of liver nuclei: possible mechanism of effect of 6-mercaptopurine on tumour growth. Nature. 1961 Dec 9;192:946–948. doi: 10.1038/192946a0. [DOI] [PubMed] [Google Scholar]
  3. CONDIE R. M., GOOD R. A. Experimental allergic encephalomyelitis: its production, prevention, and pathology as studied by light and electron microscopy. Prog Neurobiol. 1959;4:321–392. [PubMed] [Google Scholar]
  4. DAMESHEK W., SCHWARTZ R. Treatment of certain "autoimmune" diseases with antimetabolites; a preliminary report. Trans Assoc Am Physicians. 1960;73:113–127. [PubMed] [Google Scholar]
  5. DAVIDSON J. D. Studies on the mechanism of action of 6-mercaptopurine in sensitive and resistant L1210 leukemia in vitro. Cancer Res. 1960 Feb;20:225–232. [PubMed] [Google Scholar]
  6. ELION G. B., BIEBER S., HITCHINGS G. H. The fate of 6-mercaptopurine in mice. Ann N Y Acad Sci. 1954 Dec 6;60(2):297–303. doi: 10.1111/j.1749-6632.1954.tb40020.x. [DOI] [PubMed] [Google Scholar]
  7. FERRARO A., ROIZIN L. Experimental allergic encephalomyelitis during and following cortone acetate treatment. J Neuropathol Exp Neurol. 1953 Oct;12(4):373–386. doi: 10.1097/00005072-195312040-00005. [DOI] [PubMed] [Google Scholar]
  8. FIELD E. J. Effect of x-irradiation upon the development of experimental allergic encephalomyelitis in guines-pigs. Br J Exp Pathol. 1961 Aug;42:303–306. [PMC free article] [PubMed] [Google Scholar]
  9. FIELD E. J. Experimental allergic encephalomyelitis. Proc R Soc Med. 1961 Jan;54:15–18. [PMC free article] [PubMed] [Google Scholar]
  10. GENGHOF D. S., BATTISTO J. R. Antibody production in guinea pigs receiving 6-mercaptopurine. Proc Soc Exp Biol Med. 1961 Aug-Sep;107:933–936. doi: 10.3181/00379727-107-26801. [DOI] [PubMed] [Google Scholar]
  11. GOOD R. A., CAMPBELL B., GOOD T. A. Prophylactic and therapeutic effect of para-aminobenzoic acid and sodium salicylate on experimental allergic encephalomyelitis. Proc Soc Exp Biol Med. 1949 Nov;72(2):341–347. doi: 10.3181/00379727-72-17426. [DOI] [PubMed] [Google Scholar]
  12. HOYER L. W., CONDIE R. M., GOOD R. A. Prevention of experimental allergic encephalomyelitis with 6-mercaptopurine. Proc Soc Exp Biol Med. 1960 Jan;103:205–207. doi: 10.3181/00379727-103-25460. [DOI] [PubMed] [Google Scholar]
  13. KABAT E. A., WOLF A., BEZER A. E. Studies on acute disseminated encephalomyelitis produced experimentally in rhesus monkeys. VII. The effect of cortisone. J Immunol. 1952 Mar;68(3):265–275. [PubMed] [Google Scholar]
  14. KOLB L. C., KARLSON A. G., SAYRE G. P. Prevention of experimental allergic encephalomyelitis by various agents. Trans Am Neurol Assoc. 1952;56(77TH):117–121. [PubMed] [Google Scholar]
  15. LAPLANTE E. S., CONDIE R. M., GOOD R. A. Prevention of secondary immune response with 6-mercaptopurine. J Lab Clin Med. 1962 Apr;59:542–549. [PubMed] [Google Scholar]
  16. MANDEL H. G. The physiological disposition of some anticancer agents. Pharmacol Rev. 1959 Dec;11:743–838. [PubMed] [Google Scholar]
  17. MOYER A. W., JERVIS G. A., BLACK J., KOPROWSKI H., COX H. R. Action of adrenocorticotropic hormone (ACTH) in experimental allergic encephalomyelitis of the guinea pig. Proc Soc Exp Biol Med. 1950 Nov;75(2):387–390. doi: 10.3181/00379727-75-18207. [DOI] [PubMed] [Google Scholar]
  18. PAGE A. R., CONDIE R. M., GOOD R. A. Effect of 6-mercaptopurine on inflammation. Am J Pathol. 1962 May;40:519–530. [PMC free article] [PubMed] [Google Scholar]
  19. PHILIPS F. S., STERNBERG S. S., HAMILTON S., CLARKE D. A. The toxic effects of 6-mercaptopurine and related compounds. Ann N Y Acad Sci. 1954 Dec 6;60(2):283–296. doi: 10.1111/j.1749-6632.1954.tb40019.x. [DOI] [PubMed] [Google Scholar]
  20. SCHWARTZ R., STACK J., DAMESHEK W. Effect of 6-mercaptopurine on antibody production. Proc Soc Exp Biol Med. 1958 Oct;99(1):164–167. doi: 10.3181/00379727-99-24281. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES